NCT05264038View on ClinicalTrials.gov

A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

September 7, 2022

Study Completion Date

March 13, 2023

Conditions
Cancer Cachexia
Interventions
DRUG

OC514 (Low dose)

Low dose level of OC514

DRUG

OC514 (Mid dose)

Mid dose level of OC514

DRUG

OC514 (High dose)

High dose level of OC514

OTHER

Placebo

Placebo to match

Trial Locations (1)

Unknown

Nucleus network, Melbourne

All Listed Sponsors
lead

Oncocross Australia Pty Ltd.

INDUSTRY